GAK and prostate carcinoma: Although EGFR [15] and GAK [8] are expressed at high levels in prostate cancer and their enhanced expression is associated with poor prognosis [8], [15], administration of gefitinib alone is ineffective [16] and combined administrations of gefitinib and radiation therapy [17] or docetaxel [18] have limited therapeutic effects.